slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 47,251-47,280
Pages 3,679
Rows per page 30
Component
47,251-47,280 of 110,355
127
The slide uses a red box to highlight specific text in the source material to support the claim of burying data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
128
The slide highlights a 'cut-and-paste' error where the visual structure of the graph is identical between two sources, but the underlying data points (HbA1c values) have been altered.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
129
The slide uses visual annotations (red arrows and brackets) to highlight data manipulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
130
The slide uses a line chart with error bars to compare 'Original Data' vs 'New Data' to highlight data manipulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
131
Uses a 'before-after' comparison to highlight data inconsistency as evidence of fraud.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
132
The slide uses a line chart to demonstrate that the fasting glucose values are identical to a previous study (Miller et al 2024), implying the new HbA1c claims are fabricated.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
133
The slide highlights that GH induces insulin resistance while DCCR blocks insulin release, creating a synergistic risk for hyperglycemia.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
134
The slide uses a direct quote and an abstract excerpt to build credibility for the argument that GH therapy has negative metabolic consequences.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
135
The slide uses direct excerpts from the FDA label to contrast with the company's reported clinical findings.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
136
The slide uses a 'two-hit' metaphor to describe the synergistic risk of the two medications.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
138
The slide uses a list of 6 risk factors to build a medical case for why the drug's side effects are particularly dangerous for this specific patient group.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
139
The slide uses a combination of a table excerpt and a text excerpt to highlight a specific reporting discrepancy.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
140
Uses red boxes and arrows to visually connect the contradictory data points.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
141
The red box highlights the 30.4% peripheral edema rate. The text argues that the conflation of data between the P3 study and the extension study is an intentional attempt to hide worsening safety profiles.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
142
The slide uses medical definitions to frame the clinical trial results as evidence of adverse effects (edema) related to the drug DCCR.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
143
The slide uses a causal chain structure to explain the side effect.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
144
The slide uses a medical illustration to show the impact of fluid retention on heart chambers (diastolic vs systolic).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
145
The slide uses red annotations to re-interpret the company's original chart data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
146
The slide uses a technical explanation of DEXA limitations to undermine the company's reported clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
147
The slide uses a table to highlight inconsistencies in clinical trial data to suggest misclassification of medical outcomes.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
148
The slide uses a table to map shared mechanisms of edema between GH and Diazoxide, and a second table to highlight the high prevalence of GH use in the P3 study.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
149
The slide uses red boxes to highlight specific text in the protocol that contradicts the lack of reporting in the final study.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
150
The slide uses a direct quote from a physician to undermine the company's marketing claims.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
151
The slide uses expert testimony to highlight a potential safety concern (edema) and suggests the company is downplaying or managing it in an unusual way.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
152
The slide uses direct quotes from a KOL to build a case against the safety of a drug (Vykat) in the PWS population.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
153
The slide uses a combination of medical argumentation and cited research conclusions to highlight the risks of a specific drug regimen.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
154
The slide uses direct quotes from pediatric endocrinologists to highlight safety concerns, specifically referencing the drug's potential to exacerbate existing cardiac risks in PWS patients.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
155
The slide uses Q&A transcripts to expose the risks associated with the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
157
Uses social media follower counts as a proxy for community size to highlight the lack of engagement with the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
158
The slide highlights the discrepancy between the expected community interest and the actual low membership/activity numbers.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit